
Table of Contents

Chapter 1 Introduction

1.1. Introduction	1
1.2. Objective of the proposed work:.....	8
1.3. Rationale.....	8
1.4. Hypothesis:	9
1.5. Research Plan: Aims & Objective	9
1.6. Expected Results.....	9
1.7. Work Plan.....	10
1.8. References	11

Chapter 2 Literature Survey

2.1 Cystic Fibrosis:	15
2.1.1 Epidemiology.....	15
2.1.2 Pathogenesis	16
2.1.3 Co-morbidities with CF.....	17
2.1.4 Diagnosis	18
2.1.5 Treatment.....	18
2.1.5.1 Airway clearance techniques.....	18
2.1.5.2 Chronic pulmonary drugs.....	19
2.1.5.3 Gene therapy.....	19
2.2 CF Gene Therapy.....	19
2.2.1 Problems with CFTR gene transfer	20
2.3 ENaC as therapeutic target CF	21
2.4 RNA interference.....	23

2.5	Delivery of siRNA	25
2.5.1	Barriers in siRNA delivery	26
2.5.2	Role of vectors in delivery of siRNA	29
2.5.2.1	Liposomes and lipid-like materials.....	30
2.5.2.2	Polymers.....	31
2.5.3	Polyethylenimine.....	32
2.5.4	Chitosan.....	37
2.6	Pulmonary delivery	41
2.6.1	Physiological considerations	41
2.6.2	Pulmonary delivery platforms	43
2.6.2.1	Inhalation route.....	43
2.6.2.2	Intratracheal route.....	45
2.6.2.3	Intranasal route	46
2.7	References	47

Chapter 3 Analytical methods

3.1.	Selection of siRNA	67
3.2.	Characterization of siRNA	68
3.3.	Analytical Method Development.....	69
3.3.1	Materials and instruments	69
3.3.2	UV Spectrophotometric Analysis of siRNA	69
	Quantification:	69
	Purity:	70
	A260/280.....	70
	A260/A230	70

Method verification.....	71
3.3.3 Gel electrophoresis	71
3.4. Result and discussion:	73
3.4.1 Characterization of siRNA	73
3.4.2 Analytical methods	76
3.4.3 Gel electrophoresis.....	79
3.5. References:	86

Chapter 4 Development of PEI based non-viral delivery

4.1 Introduction	89
4.2 Experimental.....	90
4.2.1 Materials and chemicals	90
4.2.2 Modification of LPEI	90
4.2.3 Characterization	91
4.2.3.1 Fourier transform infrared spectroscopy (FT-IR).....	91
4.2.3.2 Nuclear magnetic resonance (NMR) spectroscopy	91
4.2.3.3 Degree of substitution	91
4.2.3.4 Solubility	91
4.2.3.5 Proton sponge	92
4.2.3.6 Preparation of polyplex	93
4.2.3.7 Gel retardation assay	93
4.2.3.8 Size and zeta.....	93
4.2.3.9 Complexation efficiency	93
4.2.3.10 Determination of siRNA Integrity	94
4.2.4 Biocompatibility studies.....	94

4.2.4.1	Hemolysis study	94
4.2.4.2	Erythrocytes aggregation	94
4.2.5	Cytotoxicity of polymer	95
4.2.6	Stability challenge studies	96
4.2.6.1	Salt induced aggregation	96
4.2.6.2	Heparin displacement assay	96
4.2.6.3	Serum stability study.....	96
4.2.6.4	Stability in bronchoalveolar lavage Fluid	97
4.2.7	Transmission electron microscopy (TEM).....	97
4.3	Result and discussion	98
4.3.1	Characterization of LPEI.....	98
4.3.2	Solubility	100
4.3.3	Proton sponge	101
4.3.4	Preparation of polyplex	103
4.3.5	Gel retardation assay	103
4.3.6	Size and zeta potential.....	106
4.3.7	Complexation efficiency	108
4.3.8	Determination of siRNA integrity	108
4.3.9	Biocompatibility study	109
4.3.9.1	Hemolysis.....	109
4.3.9.2	Erythrocyte aggregation study.....	111
4.3.9.3	Cytotoxicity of the polymer	113
4.3.10	Stability challenge studies	114
4.3.10.1	Salt induced aggregation	114

4.3.10.2	Heparin displacement assay	115
4.3.10.3	Serum stability study.....	117
4.3.10.4	Stability in bronchoalveolar lavage fluid	119
4.3.11	TEM.....	120
4.4	Reference.....	122

Chapter 5 Development of chitosan based vector for siRNA Delivery

5.1	Introduction	129
5.2	Experimental.....	130
5.2.2	Overcoming physical instability of chitosan	130
5.2.2.1	Preparation of low molecular weight chitosan (LMWC).....	130
5.2.2.2	Characterization of LMWC.....	130
5.2.3	Overcoming siRNA binding of LMWC.....	131
5.2.3.1	Preparation of LMWC-Protamine conjugate	131
5.2.4	Characterization of conjugate.....	133
5.2.4.1	Determination of conjugation efficiency	133
5.2.4.2	Preparation of Polyplex.....	135
5.2.4.3	Complexation Efficiency	135
5.2.4.4	Size and zeta potential.....	135
5.2.4.5	Cytotoxicity of polymer conjugate	136
5.2.5	Stabilization of complexes	136
5.2.5.1	siRNA location	136
5.2.5.2	TPP crosslinking	136
5.2.6	Stability challenge studies	137
5.2.6.1	Heparin challenge study	137

5.2.6.2	Serum Stability	137
5.2.6.3	Stability in brochoalveolar lavage fluid	137
5.2.7	Transmission electron microscopy	137
5.2.8	Proton sponge	137
5.3	Result and Discussion	138
5.3.1	Preparation and characterization of LMWC	138
5.3.2	Preparation and characterization of LMWC-PS conjugate	140
5.3.2.1	Complexation efficiency	145
5.3.2.2	Size and zeta potential.....	148
5.3.2.3	Cytotoxicity study.....	149
5.3.3	Stabilization of polyplex	150
5.3.3.1	siRNA location	150
5.3.3.2	TPP cross-linking.....	151
5.3.4	Stability challenge studies	152
5.3.4.1	Heparin challenge study.....	152
5.3.4.2	Serum Stability Study	154
5.3.4.3	Stability in brochoalveolar lavage fluid	155
5.3.5	Proton Sponge.....	156
5.3.6	Transmission Electron Microscopy	157
5.4	References:	158

Chapter 6 *In Vitro* Evaluation

6.1	Introduction	164
6.1.1	Cell Culture	166
6.1.2	Culturing Protocol.....	166

6.1.3	Cell Counting using haemocytometer.....	167
6.2	Experimental.....	168
6.2.1	Cytotoxicity of polyplexes	168
6.2.2	Cell uptake.....	169
6.2.2.1	Confocal microscopy	169
6.2.2.2	FACS.....	171
6.2.3	Gene knockdown efficiency	173
6.2.3.1	Selection of primers	174
6.2.3.2	Total RNA isolation	175
6.2.3.3	RNA to cDNA conversion	176
6.2.3.4	Real Time PCR.....	177
6.3	Result and Discussion	178
6.3.1	PEI based delivery Systems	178
6.3.1.1	Cytotoxicity of polyplex	178
6.3.1.2	Confocal microscopy	178
6.3.1.3	FACS.....	181
6.3.1.4	RT-PCR.....	183
6.3.2	Chitosan based vector	185
6.3.2.1	Cytotoxicity of polymer	185
6.3.2.2	Confocal microscopy	186
6.3.2.3	FACS.....	188
6.3.2.4	RT-PCR.....	189
6.4	References	191

Chapter 7 Development of Dry Powder Inhaler

7.1	Introduction	193
7.2	Materials	195
7.3	Preparation and characterization of DPI	195
7.3.1	Optimization of lyophilization.....	195
7.3.2	Moisture content	197
7.3.3	Powder processing and preparation of DPI.....	197
7.3.4	In-vitro deposition studies	197
7.3.5	Spectrofluorometric estimation of rhodamine B	197
7.3.6	Aerodynamic particle size	198
7.3.7	Scanning electron microscopy.....	199
7.3.8	X-ray diffraction (XRD).....	199
7.3.9	Integrity of siRNA	199
7.3.10	Animal studies	199
7.3.10.1	Animals:.....	200
7.3.10.2	Administration of doses:.....	200
7.3.10.3	Clinical observations	200
7.3.10.4	Bronchoalveolar fluid examination.....	201
7.3.10.5	Histopathological examination of lung	201
7.3.11	Stability studies.....	201
7.3.12	Statistical analysis.....	201
7.4	Result and Discussion	202
7.4.1	Optimization of lyophilization.....	202
7.4.2	Powder processing and preparation of DPI	204
7.4.3	Spectrofluorometric estimation of rhodamine B	205

7.4.4	Aerosolization performance of dry powder for inhalation.....	207
7.4.5	Scanning electron microscopy.....	210
7.4.6	XRD	211
7.4.7	Animal studies	211
7.4.8	Stability studies.....	213
7.5	References	215
Chapter 8	Summary and Conclusion	217

List of Tables

Table 2.1: Comparison of shift of second protonation constant in multi-amines	36
Table 2: Factors governing deposition of particles in lung.....	42
Table 3.1: Obtained concentration of siRNA at 260 nm	77
Table 3.2: Results of accuracy measurements	78
Table 3.3: Inter-day precision of the method.....	79
Table 3.4: Optimized parameters for gel electrophoresis	81
Table 3.5: Relative band densities at different siRNA concentrations	83
Table 4.1: Degree of substitution determined by ¹ HNMR	99
Table 4.2: Summary of polymer characteristics.....	102
Table 4.3: The n/p ratio required for complete gel retardation.....	104
Table 4.4: Particle size and zeta potential of LPEI and HELPEI polyplexes	107
Table 4.5: Complexation efficiency at the optimized n/p ratio.....	108
Table 4.6: Electrolyte induced flocculation of polyplex	115
Table 4.7: Serum stability of polyplex as compared to naked siRNA	118
Table 4.8: Stability of polyplexes in BALF.....	119
Table 5.1: The calculated intrinsic viscosity of Chitosan and LMWC fragments	139
Table 5.2: Results of Accuracy measurements	144
Table 5.3: Inter and Intra-day Precision	144
Table 5.4: Robustness of method for change in α -Naphthol addition.....	145
Table 5.5: Conjugation efficiency of the conjugates.....	145
Table 5.6: Complexation efficiency at the optimized weight ratios.....	148
Table 5.7: Size determined at optimized polymer to siRNA weight ratios	149
Table 5.8: Effect of TPP cross-linking on physicochemical parameter	152
Table 5.9: % siRNA retained during the course of serum stability study	156
Table 5.10: % siRNA retained by polyplexes in BALF	156
Table 6.1: Cell line treatment parameters for confocal microscopy and flow cytometry of LPEI based formulations	171
Table 6.2: Cell line treatment parameters for confocal microscopy and flow cytometry for chitosan based formulations	171
Table 6.3 Details of primers.....	176

Table 6.4 RNA to cDNA conversion parameters.....	177
Table 6.5 Steps of PCR cycle.....	177
Table 6.6 mRNA quantification – reaction parameters	177
Table 6.7 RT-PCR cycle steps refer the stages below for details	178
Table 6.8: Uptake of various formulations in CFBE 41o- cells.....	181
Table 6.9: Quantitative cell uptake of various formulations.....	189
Table 7.1: Optimization of lyophilization for HELPEI-35	203
Table 7.2: Optimization of lyophilization for LMWC-29-PS-12.....	203
Table 7.3 Results of accuracy measurements.....	206
Table 7.4 Inter and intra-day precision of the method.....	207
Table 7.5 Characterization of aerodynamic behavior using inhalac 230 as carrier	208
Table 7.6 Characterization of aerodynamic behaviour using respitose SV001 as carrier..	209
Table 7.1: Results of stability study (mean± SD)	214

List of Figures

Fig. 2.1: Protonation state of LPEI backbone	35
Fig. 2.2: pKa values of chitosan with degree of deacetylation	38
Fig. 2.3: Mechanism of nitrous acid mediated depolymerization of chitosan	39
Fig. 3.1: MALDI analysis of sense strand of siRNA showing m/z value	74
Fig. 3.2: Capillary gel electrophoresis of siRNA showing purity in the form of single peak	75
Fig. 3.3: MALDI analysis of antisense strand of siRNA showing m/z value.....	75
Fig. 3.4: Capillary gel electrophoresis antisense strand of siRNA showing purity	76
Fig. 3.5: Purity and concentration determination of siRNA using NanoDrop.....	76
Fig. 3.6: Correlation of known concentration of siRNA Vs NanoDrop results.....	77
Fig. 3.7: Typical band distortion observed during Gel Electrophoresis	80
Fig. 3.8: Effect of vehicle of siRNA by gel retardation assay	80
Fig. 3.9: siRNA stock solution stability to repeat sampling	81
Fig. 3.10: Estimation of minimum quantity of siRNA by gel retardation assay.....	82
Fig. 3.11: Gel Electrophoresis Band Densities at different siRNA Concentrations	83
Fig. 3.12: The correlation curve for prepared siRNA concentration and relative band density	84
Fig. 3.13: Accuracy and Precision of Gel Electrophoresis Method for siRNA Quantification	84
Fig. 4.1: IR overlay of LPEI and HELPEI.....	98
Fig. 4.2: A) Illustrative scheme for preparation B) ¹ HNMR spectrum of LPEI; C) ¹ HNMR spectrum of HELPEI-45	99
Fig. 4.3: Summary plot of transmittance of LPEI and HELPEI at different pH.....	100
Fig. 4.4: Titration of LPEI and HELPEI with 0.1 N HCl.....	102
Fig. 4.5: Gel retardation of LPEI.....	104
Fig. 4.6: Gel retardation assay of HELPEI-15.....	104
Fig. 4.7: Gel retardation assay of HELPEI-25.....	105
Fig. 4.8: Gel retardation assay of HELPEI-35.....	105
Fig. 4.9: Gel retardation assay of HELPEI-45.....	105
Fig. 4.10: Malvern Zeta sizer report of HELPEI-35 polyplex.....	107
Fig. 4.11: Malvern Zeta Potential Report of HELPEI-35 polyplex	107

Fig. 4.12: Figure showing the integrity of siRNA.....	108
Fig. 4.13: Result of hemolysis study of LPEI.....	110
Fig. 4.14: Result of hemolysis study of HELPEI 35	110
Fig. 4.15: Hemolytic potential of different HELPEIs at different concentrations.	110
Fig. 4.16: Results of erythrocyte aggregation study for LPEI and HELPEIs.....	112
Fig. 4.17: Comparison of cytotoxicity of polymers	114
Fig. 4.18: Electrolyte induced flocculation of polyplex.	115
Fig. 4.19: Heparin displacement of LPEI	116
Fig. 4.20: Heparin displacement of HELPEI-35.....	116
Fig. 4.21: Heparin displacement of HELPEI-45.....	116
Fig. 4.22: Gel electrophoresis of serum stability	118
Fig. 4.23: siRNA retained in polyplex at different time points in presence of BALF	119
Fig. 4.24: TEM image of A) HELPEI-35 polyplex, B) HELPEI-45 polyplex	120
Fig. 5.1: Representative plot for intrinsic viscosity calculation (LMWC-88).....	139
Fig. 5.2: Solubility profile of different molecular weight chitosan.....	140
Fig. 5.3: Spectral overlay of different calibration standards.....	142
Fig. 5.4: calibration of colorimetric method for estimation of PS	143
Fig. 5.5: The overlay of spectra of PS and chitosan showing absence of interference	144
Fig. 5.6: Gel retardation assay of MMWC	146
Fig. 5.7: Gel retardation assay of LMWC-29	146
Fig. 5.8: Gel retardation assay of PS	147
Fig. 5.9: Gel retardation assay of LMWC-29-PS-12 conjugate.....	147
Fig. 5.10: MTT assay for cytotoxicity of chitosan polymers.....	150
Fig. 5.11: Gel retardation showing location of siRNA.....	151
Fig. 5.12: Confirmation of siRNA in retarded wells after displacing with heparin.....	151
Fig. 5.13: Heparin resistance of LMWC-29 polyplex	153
Fig. 5.14: Heparin resistance of LMWC-29-PS-12 polyplex	153
Fig. 5.15: Heparin resistance after TPP cross-linked LMWC-29-PS-12 polyplex	154
Fig. 5.16: Gel electrophoresis of serum stability	155
Fig. 5.17: siRNA retained in polyplex at different time points in presence of BAL	157
Fig. 5.18: Proton sponge study of chitosan based vectors.....	158

Fig. 5.19: TEM image of TPP cross-linked LMWC-29-PS-12 polyplex	158
Fig. 6.1: Comparison of cytotoxicity of siRNA polyplexes	178
Fig. 6.2: Cell uptake of screened formulations by confocal microscopy; A) Naked siRNA, B) LPEI, C) HELPEI-35, D) HELPEI-45, E) L2K.....	180
Fig. 6.3: Histogram plots from flow cytometer after cell uptake study A) unstained control, B) naked siRNA, C) LPEI polyplexes, D) HELPEI-35 polyplexes, E) HELPEI-45 polyplexes, F) L2K.....	182
Fig. 6.4: % cell uptake observed in FACS study of prepared polyplexes	183
Fig. 6.5: Melt Curve for RT-PCR: ENaC (Blue color), GAPDH (Green color)	184
Fig. 6.6: % Gene expression in CFBE41o- cells after treatment LPEI based formulations	185
Fig. 6.7: MTT assay for cytotoxicity of chitosan based polyplexes	186
Fig. 6.8: Confocal microscopy images of A) FAM-NC-siRNA, B) MMWC, C) LMWC-29, D) PS, E) LMWC-29-PS-12, F) L2K.....	187
Fig. 6.9: Results of FACS analysis of different polyplexes A) Untreated cells B) Naked FAM-NC-siRNA, C) MMWC polyplexes, D) LMWC-29 polyplexes, E) PS polyplexes, F) LMWC-29-PS-12 polyplexes, G) L2K.....	188
Fig. 6.10: % cell uptake observed in FACS.....	189
Fig. 6.11: % gene expression in CFBE 41o- cells after treatment with various formulations	190
Fig. 7.1: Effect of freezing rate on super cooling.....	202
Fig. 7.2: Optimization of lyophilization for HELPEI-35 polyplexes: 1) mannitol, 2) trehalose, 3) sucrose; LMWC-29-PS-12 polyplexes: 4) mannitol, 5) trehalose, 6) sucrose	204
Fig. 7.3: Result analysis report of Malvern Mastersizer after powder after size reduction	205
Fig. 7.4: Spectrofluorometric spectra of Rhodamine B.....	206
Fig. 7.5: Calibration curve for Rhodamine B	206
Fig. 7.6: In vitro pulmonary deposition of pater of dry powder formulations.....	209
Fig. 7.7: A) Integrity of siRNA from HELPEI-35 DPI formulation (Lane 1: Naked siRNA, Lane 2: After lyophilization, Lane 3: After powder processing); B) Integrity of siRNA from CSPS conjugate DPI formulation (Lane 1: Naked siRNA, Lane 2: After lyophilization, Lane 3: After powder processing).....	210
Fig. 7.8: SEM image of the optimized blend for DPI formulation	210

Fig. 7.9: XRD image of developed DPI after powder processing211

Fig. 7.10: Results of lung weight analysis and BALF examination.....212

Fig. 7.11: Histological analyses of lung in hematoxylin and eosin stained sections after treatment with (1) Saline, (2) LPS, (3) LPEI formulation, (4) HELLPEI-35 formulation, (5) LMWC-29-PS-12 formulation.....213